We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.
He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...
Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to ...
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback